Atlas Trials

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Clinical trial NCT04954001 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04954001
Sponsor
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Neurofibromatosis 1Plexiform NeurofibromaNF1
Start date
2021-03-26
Primary completion
2025-02-28
Enrollment
160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.